title: Adverse effects of golimumab in the treatment of rheumatologic diseases.
abstract: BACKGROUND
  A number of new biological immune modulators have become available as treatments for inflammatory diseases over the past two decades. Most prominent among them are TNF-α inhibitors (TNFi) which have been available in the clinic since the late 1990s. TNFi have demonstrated efficacy in various rheumatologic diseases as well as in inflammatory bowel disease and psoriasis. Golimumab is one of the most recently introduced TNFi.
  
  
  METHODS
  Although golimumab is generally well tolerated, as is the case with other TNFi and indeed with most of the marketed immunomodulatory drugs, potential adverse events may be associated with its use. Herein, we the potential adverse effects associated with golimumab therapy are reviewed. Adverse effects are divided into target-related and agent-related categories.
  
  
  CONCLUSIONS
  Golimumab has been demonstrated to be generally safe and well tolerated. Its safety profile seems to be very comparable to the other available TNFi. Long-term studies of golimumab and other TNFi will help establish the durability of response to golimumab as well as identify any potential delayed or cumulative adverse effects.
authors.affiliation: University of California, Division of Rheumatology, Allergy and Immunology , 9500 Gilman Drive, MC 0943, La Jolla, CA, 92093-0943 , USA hoy004@AD.UCSD.EDU.
authors.forename: Hong
authors.initials: H
authors.lastname: Yang
authors.forename: Arthur
authors.initials: A
authors.lastname: Kavanaugh
mesh_terms: D000911:Antibodies, Monoclonal / Q000009:adverse effects* / Q000494:pharmacology / Q000627:therapeutic use; D018501:Antirheumatic Agents / Q000009:adverse effects* / Q000494:pharmacology / Q000627:therapeutic use; D006801:Humans; D012216:Rheumatic Diseases / Q000188:drug therapy* / Q000503:physiopathology; D014409:Tumor Necrosis Factor-alpha
chemical_list: D000911:Antibodies, Monoclonal; D018501:Antirheumatic Agents; D014409:Tumor Necrosis Factor-alpha; C529000:golimumab